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AbstrACt
Introduction Prevention of fragility fractures, a source of 
significant economic and personal burden, is hindered by 
poor uptake of fracture prevention medicines. Enhancing 
communication of scientific evidence and elicitation 
of patient medication- related beliefs has the potential 
to increase patient commitment to treatment. The 
Improving uptake of Fracture Prevention drug treatments 
(iFraP) programme aims to develop and evaluate a 
theoretically informed, complex intervention consisting 
of a computerised web- based decision support tool, 
training package and information resources, to facilitate 
informed decision- making about fracture prevention 
treatment, with a long- term aim of improving informed 
treatment adherence. This protocol focuses on the iFraP 
Development (iFraP- D) work.
Methods and analysis The approach to iFraP- D is 
informed by the Medical Research Council complex 
intervention development and evaluation framework 
and the three- step implementation of change model. 
The context for the study is UK fracture liaison services 
(FLS), which enact secondary fracture prevention. An 
evidence synthesis of clinical guidelines and Delphi 
exercise will be conducted to identify content for the 
intervention. Focus groups with patients, FLS clinicians 
and general practitioners and a usual care survey will 
facilitate understanding of current practice, and investigate 
barriers and facilitators to change. Design of the iFraP 
intervention will be informed by decision aid development 
standards and theories of implementation, behaviour 
change, acceptability and medicines adherence. The 
principles of co- design will underpin all elements of the 
study through a dedicated iFraP community of practice 
including key stakeholders and patient advisory groups. 
In- practice testing of the prototype intervention will inform 
revisions ready for further testing in a subsequent pilot and 
feasibility randomised trial.
Ethics and dissemination Ethical approval was 
obtained from North West—Greater Manchester West 
Research Ethics Committee (19/NW/0559). Dissemination 
and knowledge mobilisation will be facilitated through 
national bodies and networks, publications and 
presentations.
trial registration number researchregistry5041.
IntroduCtIon
In the UK, 3 million people are estimated 
to have osteoporosis,1 contributing to over 
500 000 fragility fractures (fractures resulting 
from low trauma) per year, costing an 
strengths and limitations of this study
 ► A robust intervention development process will in-
corporate multiple sources of evidence, informed by 
the Medical Research Council framework for devel-
oping complex interventions and a three- step model 
of change.
 ► A comprehensive logic model and use of the ne-
cessity concerns framework provides a theoretical 
basis for enhancing informed adherence.
 ► Collaboration with patients and clinicians, using the 
principles of co- design, and use of the theoretical 
framework of acceptability to analyse qualitative 
data will enable us to iteratively develop an inter-
vention that is relevant and acceptable to users.
 ► Improving uptake of Fracture Prevention drug treat-
ments will be designed to address barriers to im-
plementation from the outset, through the use of 
normalisation process theory, theoretical domains 
framework and the Capabilities, Opportunities and 
Motivation Behaviour- Based Theory of Change 
Model (COM- B), and will produce evidence on barri-
ers and facilitators to implementation.
 ► The research will be conducted in the UK, with in- 
practice testing conducted at one site; it is possible 
that barriers and facilitators to change, and the rele-
vance of our intervention may vary across FLS sites, 
different contexts (eg, in primary care) and geo-
graphical locations (nationally and internationally).
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estimated £4.4 billion per annum.2 Fragility fractures 
can be devastating, sometimes resulting in loss of inde-
pendence and mortality.3 Hip fractures alone account 
for 85 000 unplanned hospital admissions and 1.8 million 
bed- days in the UK per year.4 Evidence- based treatments, 
such as bisphosphonates, are recommended by the 
National Institute for Health and Care Excellence (NICE) 
for patients with osteoporosis and/or a high fracture risk. 
They are inexpensive, cost- effective, readily available and 
reduce fracture risk by 20%–70% (depending on fracture 
site).5 Despite this, a treatment gap exists. Up to 80% 
of patients who experience a fragility fracture do not 
receive medication in the year following fracture,6 25% 
of people who are offered medication decline it (non- 
initiation)7 and among those who do start bisphospho-
nates, few persist for long enough for it to be effective, 
with adherence estimated at 16%–60% at 1 year.8 Closing 
this treatment gap may prevent at least 20 000 hip frac-
tures annually in the UK.4
Patient reasons for non- initiation and non- persistence 
of oral bisphosphonates (the mainstay of osteoporosis 
treatment) are complex and include: perceptions that 
drugs are not effective, not necessary and/or not safe; 
limited understanding of the consequences of non- 
treatment and concerns about perceived or experienced 
side effects.9 10 Despite national osteoporosis guidance 
recommending the provision of information as a core 
component of management,11 patients report that osteo-
porosis information provided in consultations is often not 
easy to understand.12 Some primary care clinicians believe 
that bisphosphonates are not safe, effective or necessary.13 
The more recent shift to base treatment recommenda-
tions on fracture risk rather than bone density readings,14 
is not without challenge: patients struggle to understand 
fracture risk assessments15 and frequently underestimate 
their risk of fracture.16 This suggests unmet health literacy 
needs and patients have identified improving access to 
information from health professionals as the number one 
patient priority for osteoporosis research.17
Patients ultimately decide whether to start and continue 
taking medication, but this decision- making is influenced 
by the clinician- patient interaction. In order to decide to 
start and persist with medication, patients need to believe 
that recommended drug treatment is necessary, rele-
vant, safe and practicable. Effective communication that 
enables patients to understand complex medical terms 
and concepts in lay terms, increases patient satisfaction, 
facilitates participation in the consultation, promotes 
trust18 and may increase patients’ commitment to medi-
cation.19 This highlights the relevance of promoting and 
supporting effective communication between clinician 
and patients, and suggests that improving communica-
tion of the harms and benefits of osteoporosis medica-
tions may be beneficial in reducing the treatment gap.
Decision aids (DAs) include numerical estimates of 
risk/benefit. They can facilitate improved risk commu-
nication and support patient decision- making before or 
during healthcare consultations.20 21 When used across 
a range of conditions, DAs can increase patient knowl-
edge, reduce decisional conflict, increase patient partic-
ipation in decision- making and improve the accuracy of 
risk perception.20 A recent Cochrane review reported 
high- quality evidence that DAs, across a range of condi-
tions, increase patient knowledge and reduce decisional 
conflict, and moderate- quality evidence that DAs increase 
patient participation in decision- making and improve 
the accuracy of risk perception.20 Increases in knowledge 
and informed choice were also reported in studies where 
health literacy needs were addressed.22 Evidence from 
pooled analyses of studies where there was no equipoise 
(meaning that DAs were used to give information about 
recommended drug treatments, rather than to choose 
between treatment options with perceived equal bene-
fits), has indicated that DAs improve treatment initiation 
rates.20 In osteoporosis, use of DAs can increase accuracy 
of risk perception and shared decision- making. However, 
existing osteoporosis DAs fail to comprehensively meet 
international quality standards and patient needs,23 
underlining the requirement for further development.
DAs are sometimes called decision support tools 
(DSTs), particularly when tools also contain clinician 
decision support. DSTs can also support clinicians to 
follow evidence- based practice and have been shown to 
improve adherence to evidence- based guidelines.24 25
The Improving uptake of Fracture Prevention drug treat-
ments (iFraP) programme aims to develop and evaluate a 
theoretically informed, complex intervention consisting 
of a computerised (C)DST, training package and infor-
mation resources to facilitate informed decision- making 
about fracture prevention treatment, with a long- term 
aim of improving informed treatment adherence. This 
protocol is for the first study within the iFraP programme 
of work focusing on the Development of the new consul-
tation intervention, referred to as iFraP- D.
study protoCol
Aims and objectives
The iFraP- D has three overarching objectives, which are 
to:
1. develop core content for a new consultation interven-
tion (iFraP) based on theory, published guidance, sys-
tematic review evidence, a Delphi consensus exercise 
and stakeholder engagement;
2. design a prototype CDST using published guidance 
and with stakeholder engagement;
3. use qualitative methods and stakeholder engagement 
to:
a. investigate current practice, and the barriers and fa-
cilitators to, communicating fracture risk and treat-
ment benefits/harms and to delivering the iFraP in-
tervention (CDST and training package), including 
the training needs of clinicians;
b. co- design the components of the iFraP intervention 
and associated training package for clinicians;
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c. plan the integration of components in the new iF-
raP consultation intervention;
d. conduct cycles of in- practice testing to determine if 
the iFraP intervention is meeting its objectives, with 
subsequent refinement of the intervention.
overview of context and intervention
The proposed iFraP consultation intervention will be 
primarily designed for fracture liaison services (FLSs). 
These are usually nurse- led, and address secondary frac-
ture prevention by: systematically identifying patients with 
fragility fractures; assessing the patient’s bone health, 
risk of falls and future fracture and providing treatment 
recommendations to the patient and primary care. Clin-
ical standards for FLS also recommend follow- up consulta-
tions, 3 and 12 months postfracture, to support medicines 
adherence.26 Within the context of FLS, all consultations 
are concerned with future fracture prevention, which 
will maximise efficiency of recruitment and testing. The 
multidisciplinary study team will allow the relevance of 
the intervention for use in other primary and secondary 
care settings in which fracture prevention treatments are 
recommended to patients, to be considered.
The iFraP consultation intervention will support clini-
cians to:
 ► Make decisions about who is eligible for fracture 
prevention treatment, using a CDST to operationalise 
existing clinical guidelines.
 ► In patients in whom fracture prevention treatment is 
indicated:
 – Communicate the risks and benefits of fracture 
prevention treatment, including individualised 
fracture risk, using a CDST, adopting universal pre-
cautions for low health literacy.
 – Elicit patients’ understanding, and concerns about 
fracture prevention treatment.
 – Assess readiness to initiate fracture prevention 
treatments and facilitate behaviour change.
 – Communicate consultation outcomes with the 
patients’ primary care provider and facilitate con-
sistent information provision across primary and 
secondary care.
The iFraP consultation intervention will be delivered 
within FLS consultations and will include:
 ► A CDST to communicate individual fracture risk. 
This will include clinician decision- support and a 
patient- facing DA. It will be dynamic, interactive and 
tailored to risks and needs of the patient. It will incor-
porate fracture risk (calculated in external systems 
(eg, FRAX)), an indicator for clinicians of whether 
treatment is recommended, a pictorial presentation 
of individualised fracture risk, fracture risk with medi-
cation (to show benefits of treatment) and possible 
treatment harms. The CDST will be used by trained 
clinicians in a model (face- to- face or remote) consul-
tation with patients.
 ► Clinician training in delivering the consultation 
intervention, and supporting delivery of follow- up 
consultations. This will encompass a prioritised list 
of key tasks for the clinician (both information giving 
and eliciting) to undertake. The training will include 
face- to- face sessions and an e- learning package 
to introduce the intervention, coach clinicians in 
listening skills, shared decision- making skills and 
universal precautions for health literacy, and provide 
opportunities to practice using the CDST.
 ► Information resources (paper and online) for the 
patient and general practitioner to refer to after the 
initial or follow- up consultation, including a printout 
from the CDST.
theoretical frameworks underpinning iFrap development
The long- term aim of the iFraP intervention is to improve 
fracture prevention treatment uptake, thereby preventing 
future fragility fractures. The intervention is targeted 
for use by clinicians together with the patient. This will 
empower clinicians to support patient behaviour change, 
and support clinicians with the skills to elicit and address 
patient perceptions and practicalities related to treatment 
adherence. The necessity- concerns framework (NCF) will 
be used as an overarching theoretical framework when 
designing the iFraP intervention to understand patient’s 
attitudes and beliefs underpinning treatment non- 
adherence.27 The NCF suggests that medication adher-
ence is influenced by implicit judgements of personal 
need for the treatment (necessity beliefs) and concerns 
about the potential consequences of treatment.27
To optimise iFraP in terms of acceptability to clini-
cians and patients, we will use the theoretical framework 
of acceptability (TFA)28 as an overarching framework to 
inform iFraP intervention design. The TFA consists of 
seven constructs of acceptability of healthcare interven-
tions (affective attitude, burden, intervention coherence, 
ethicality, perceived expectations, opportunity cost and 
self- efficacy). These constructs will inform data collection 
and analysis.
The implementation of iFraP is informed by the Capa-
bilities, Opportunities and Motivation Behaviour- Based 
Theory of Change Model (COM- B)29 and the complemen-
tary theoretical domains famework (TDF),30 which aim to 
simplify and integrate a range of behaviour change theo-
ries. The TDF identifies 14 related domains of influence 
on behaviour. In iFraP- D, data collection will be informed 
by domains within the TDF (eg, knowledge, beliefs about 
capabilities, skills and goals). This will identify potential 
barriers and enablers for clinicians to implement iFraP 
ahead of a formal feasibility study. normalisation process 
theory (NPT)31 will underpin the investigation of the 
dynamics of implementing, embedding and integrating 
iFraP, in order to identify potential process problems 
related to implementing iFraP in the next phase of feasi-
bility testing. NPT ensures consideration of potential 
structural problems about the integration of iFraP into 
existing services.
The specific programme theory for the iFraP- D study is 
detailed in the study logic model (figure 1). This initial 
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logic model may undergo iterative changes throughout 
the iFraP programme. Throughout development, a 
health economist will define the decision problem 
enabling identification of the different elements of treat-
ment effect potentially associated with the iFraP interven-
tion and directly informing the data collection strategy, 
including primary and secondary outcomes, for the subse-
quent pilot and feasibility trial that will follow iFraP- D.
Approach to iFrap intervention development
In line with key principles of intervention development, 
our approach will be iterative, open to change and forward 
looking to future evaluation and implementation.32 The 
Medical Research Council guidance on complex inter-
vention development will be used as an overall frame-
work,33 within which we will specifically use a three- step 
implementation of change model.34 This approach incor-
porates three pragmatic questions with three steps, each 
linked to iFraP study objectives outlined previously:
 ► Step 1: “Where do we want to be?” Make a concrete 
proposal for change, and develop the content and 
format of the consultation intervention (objective 1).
 ► Step 2: “Where are we now?” Understand the current 
clinical context including barriers and facilitators to 
change (objective 3a).
 ► Step 3: “How do we get there” Develop a strategy to 
change behaviours, by designing and refining the 
prototype into a draft intervention, and field- testing 
(objective 2, 3b, 3c and 3d).
To answer the above questions, we will take actions 
common to different intervention development 
approaches;35 36 drawing on theory, empirical evidence 
from the evidence synthesis, Delphi survey, qualitative 
focus groups and in- practice testing, stakeholder engage-
ment and guidance for the development of DAs.37 38 We 
will adopt an informed design to iFraP design decision- 
making.32 39 We will frequently engage with stakeholders 
as part of our community of practice (CoP) and patient 
advisory groups (PAG) to discuss ideas generated by the 
study team and research findings.39 The informed design 
will facilitate stakeholder involvement in iFraP interven-
tion content and design decisions,39 with final design 
decision- making made and documented by the Study 
Management Group32 supported by the APEASE criteria 
(Affordability, Practicality, Effectiveness, Acceptability, 
Side- effects/safety, and Equity) where appropriate.40
Each step and linked study objective are outlined in turn 
throughout this protocol. The inter- relation between the 
three steps and methods of data collection is displayed in 
figure 2.
Co-design of the iFrap intervention
Community of practice
CoPs bring together expertise with a common concern 
or interest, with the aim of improving and learning to 
do better through regular group interaction.41 We will 
bring together relevant expertise (FLS clinicians, GPs, 
osteoporosis specialists, commissioning representatives, 
Figure 1 Improving uptake of Fracture Prevention drug treatments Development logic model. Context: consultations 
conducted in pre- existing specialist face- to- face fracture prevention services (FLS). Contexual factors: poor uptake of the 
National Institute for Health and Care Excellence/National Osteoporosis Guideline Group guidelines; disconnect in advice 
given to patient between FLS and primary care; media and wider social influences on health behaviours. CDST, computerised 
decision support tool; FLS, fracture liaison service; GP, general practitioner; HCP, healthcare professional; NHS, National Health 
Service; PA, physical activity; SDM, shared decision- making.
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patients (with experience of fracture prevention treat-
ment, supported by a patient and public engagement and 
involvement (PPIE) worker)), representatives from the 
Royal Osteoporosis Society (ROS) and Health Literacy UK 
and a behaviour change expert) in a stakeholder group 
that adopts a CoP approach.41 The CoP will provide their 
views on the iFraP intervention content, and discuss the 
findings from the evidence synthesis, Delphi study, quali-
tative focus groups and in- practice testing.
Patient and public involvement and engagement
The osteoporosis Research User Group (RUG) at Keele 
University comprises patients with experience of osteopo-
rosis and/or fragility fractures, or carers for such patients. 
These RUG members had substantial involvement in a 
previous study to identify patient and public priorities 
for research in osteoporosis, which provided the starting 
point for iFraP.17 Furthermore, the study- specific PAG 
informed and agreed how PPIE members will be involved 
throughout the iFraP programme at the outset. In addi-
tion to PAG members participating in the Study Manage-
ment Group, Award Steering Committee meetings and 
CoP meetings, approximately six study- specific PAG 
meetings will be convened throughout the iFraP research 
cycle. PAG meetings will: (i) facilitate design, analysis and 
interpretation of the Delphi study (including how best to 
recruit and explain the Delphi study to patients, piloting 
the survey and contributing to analysis), qualitative focus 
groups and in- practice testing (by informing recruitment, 
co- designing topic guide content and supporting anal-
ysis and interpretation of findings); (ii) co- design visual 
components of the CDST; (iii) informally test the CDST 
prototype before in- practice testing and (iv) provide 
advice about dissemination to the wider public, including 
what results to share, when and in what format. Additional 
information regarding PPIE is detailed throughout this 
protocol where appropriate. The Guidance for Reporting 
Involvement of Patients and the Public (GRIPP2) will be 
used in future dissemination to guide PPIE reporting.42
MEthods And AnAlysIs
The iFraP- D study began at the end of March 2019 and 
the study is expected to be completed in December 2021.
step 1: developing content and format of iFrap
In order to inform the content of the model consultation 
and the CDST components (overarching objective 1) of 
the iFraP consultation intervention, an evidence synthesis 
will be conducted of clinical guidelines, followed by 
consultation with stakeholders and a Delphi study with 
patients/carers and clinicians.
Evidence synthesis and stakeholder consultation
Search strategy
To identify osteoporosis clinical guidelines, the NHS 
Evidence electronic database will be searched using 
keywords ‘fragility fracture’ and ‘osteoporosis’ and 
Figure 2 Inter- relation between the implementation of change model and Improving uptake of Fracture Prevention drug 
treatments Development (iFraP- D) data collection methods. COM- B, Capabilities, Opportunities and Motivation Behaviour- 
Based Theory of Change Model; FLS, fracture liaison service; GP, general practitioner; NCF, necessity concerns framework; 
NPT, normalisation process theory; PPIE, patient and public engagement and involvement; SDM, shared decision- making; TDF, 
theoretical domains framework; TFA, theoretical framework of acceptability.
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‘guidelines’ for studies that fulfilled the eligibility criteria 
(online supplemental table 1). The search will be filtered 
to include guidance, quality indicators and policy and 
strategy. Guidelines that were developed, reviewed or 
revised within the 10 years prior to search inception will 
be used. Generic NICE guidance relating to conducting 
the consultation will also be included.
Patient information resources will be identified using 
a Google search. Leaflets and webpages will be selected 
because they are easily available (eg, on the internet, 
through patient organisations or places that people 
with osteoporosis might visit such as pharmacies). 
They will come from three different types of source: 
healthcare providers (UK National Health Service), 
charitable and voluntary organisations and the medical 
profession.
Selection process
Eligible guidelines will be selected on title first by one 
reviewer (ZP). Full texts will be retrieved and assessed 
if the title, summary or abstract provides insufficient 
information.
Eligible patient information resources will be selected 
by two reviewers. A pragmatic and purposive sample of 
resources that are most commonly accessed and repre-
sent the three groups of information providers will be 
selected.43
Quality appraisal
The quality of the included guidelines will be appraised 
using the Appraisal of Guidelines for Research and Eval-
uation (AGREE II) tool.44 Guidelines that score 75% or 
above will be tagged as high quality (in line with examples 
given by the AGREE II developers); this quality score will 
inform discussion in the stakeholder groups about the 
relevance of recommendations.
The overall quality of each patient information resource 
will be assessed using a modified International Patient 
Decision Aid Standards (m- IPDAS).37 The m- IPDAS 
assess patient information based on 32 items across 8 
categories of content, bias, detail, probabilities, accuracy, 
decision- making, conflict of interest, structure and layout 
and reliability.
Data extraction
Statements and recommendations from included guide-
lines that are relevant to tasks for the clinician in the 
consultation will be extracted and grouped into steps of 
phases of the consultation. Text from patient informa-
tion resources will be extracted relating to descriptions 
of osteoporosis and osteoporosis drug treatment using a 
bespoke data extraction form in excel.
Analysis
A narrative summary will report the findings of the 
guideline evidence synthesis, including textual descrip-
tion of guidelines, tabulation of recommendations 
and exploration of relationships between and within 
guidelines.
Extracted data from the patient information will be 
thematically analysed independently by two members 
of the study team using the five domains of Leventhal’s 
Common- Sense Model of Disease as a deductive frame-
work.45 Discussions will check the consistency of coding 
against the framework.
Stakeholder consultation
Evidence synthesis findings will be presented to the 
CoP for reflection on the findings and discussion of any 
inconsistencies, and discussion of how clinician tasks map 
to stages of the FLS consultation. The synthesis output 
(informed by the CoP) will form the basis of the Delphi.
Delphi study
Design
Three rounds of a modified Delphi consensus study46 
will be conducted. The Delphi approach is described as 
‘modified’, as participants will be presented with a list 
of statements to consider rather than generating their 
own list. However, in the first round, they will also have 
the opportunity to suggest additional statements for the 
consultation in free- text boxes. The aim of the Delphi is 
to make decisions about inclusion and exclusion and for 
included statements to ascertain essential and optional 
consultation content. The same survey will be developed 
for all participants (both clinical and patient/carer) to 
develop a common, understandable language. Survey 
participants will be presented with clinical vignettes and 
a list of potential content for the model consultation. 
The content will be derived from the evidence synthesis, 
informed by the CoP, and written in partnership with 
PAG members.
Participants
Patients with osteoporosis and/or fragility fractures 
and/or their carers will be recruited through the ROS 
supporters’ network. Clinicians who have experience of 
consulting with patients, where fracture risk is calculated 
and fracture prevention drug treatments are recom-
mended, will be invited to participate through ROS clini-
cian mailing lists and the study team’s clinical networks. 
Clinicians will be multidisciplinary; from primary and 
secondary care and academic settings. We aim to invite 
up to 400 participants, anticipating a 40% initial response 
rate and subsequent drop out at rounds 2 and 3, with the 
aim of achieving a final sample of 15 patients/carers and 
15 clinicians.
Data collection and analysis
In round 1, statements will be presented that relate to 
tasks of the consultation, to include clinician decision- 
making tasks and considerations, eliciting information, 
giving information, example explanations and hypothet-
ical use of the CDST, for example, ‘the patient should 
be verbally informed of their individualised fracture 
risk’, and ‘the patient should be shown a picture of their 
individualised fracture risk’. Statements will be grouped 
together under overarching headings (eg, ‘share 
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information about condition’ and ‘signpost next steps’) 
that reflect stages of the consultation (as discussed with 
the CoP). The participant will be asked to rate their 
perception of the importance of each statement on a 
5- point Likert scale.
Patient/Carer and clinician responses will be analysed 
separately. Mean scores will be calculated. Items with a 
mean importance score of <4 (range 1–5) in both patient 
and clinician surveys will be removed. Items scoring 
a mean score of <4 in either patient/carer or clinician 
survey will be individually reviewed by the Study Manage-
ment Group (including PPIE members) to make a deci-
sion about whether the item progresses to round 2, 
informed by underpinning theory, other emergent find-
ings in iFraP- D (eg, focus groups), PPIE member experi-
ences and views, etc.
In round 2, newly suggested statements in free- 
text comments, along with emerging findings from 
iFraP- D (eg, focus group findings, stakeholder (CoP 
and PPIE) experiences and views) will be added to 
statements progressing from round 1. Participants 
will be shown mean scores of importance from round 
1 and asked to re- rate the importance of each state-
ment, again using the same 5- point numeric Likert 
scale.
After round 2, statements will be ranked according to 
their mean rating score (calculated as per round 1). The 
top scoring statements from both patient/carer and clini-
cian surveys will progress to round 3, identified as those in 
the top three of four quartiles. Statements with a patient/
carer and/or clinician score in the lowest quartile will be 
reviewed by the Study Management Group (including 
PPIE members), as to whether the statement should prog-
ress to round 3, informed by the considerations described 
in round 1.
In round 3, low ranking items will be removed and 
participants will be asked to agree/disagree whether a 
statement is essential in a time- limited consultation, or 
not. Percentage agreement that ‘this item is essential in 
the time- limited consultation’ will be calculated. State-
ments will be ranked according to percentage agreement 
for both patient/carer and clinician surveys. To identify 
a set number of essential consultation statements, which 
can realistically be undertaken in a time- limited consul-
tation, we will not predefine an arbitrary level of agree-
ment for a task to be included in the iFraP consultation. 
The Study Management Group in conjunction with PPIE 
members and expert advisors will review the ranked find-
ings and identify, using their own knowledge and experi-
ence and free- text responses, where the most appropriate 
threshold is for tasks or considerations to be classified as 
‘essential’ or ‘optional’.
step 2: to understand the current clinical context of Fls 
consultations including barriers and facilitators to change
This step will involve mixed methods of data collection. 
A qualitative focus group study and a survey of usual care 
will achieve objective 3a.
Focus groups
Objective
To qualitatively explore current practice in relation to 
fracture prevention communication, anticipated barriers 
and facilitators to the iFraP intervention and perceived 
training needs for FLS clinicians.
Participants
Two focus groups with patients that have recently attended 
an FLS consultation and received a treatment recommen-
dation, two focus groups with clinicians that conduct face- 
to- face consultations with patients in UK FLSs and one 
focus group with GPs with experience of consulting with 
patients who have been seen in FLS and that work in the 
catchment of a UK FLS. Focus groups will be conducted 
with participants from different geographical areas, with 
approximately four to eight participants in each group.
Data collection
Focus groups enable investigation of practices among 
individuals and are particularly suited to studying group 
norms and processes, as group interaction is explicitly 
used to generate data and insights.47 If face- to- face focus 
groups are inappropriate, qualitative data collection 
will be conducted remotely (eg, by telephone or video 
conferencing software) and audio- recorded. A topic 
guide (informed by theory, evidence gathering and CoP/
PPIE views) will prompt, facilitate and structure discus-
sion. The guide will include questions related to the TDF 
as this framework will inform the content of training to 
enable skills development for clinicians and is there-
fore relevant to understanding how clinicians would use 
iFraP. The questions will also be informed by the TFA; 
our overarching TFA enabling the investigation of seven 
constructs of acceptability. Topic guides will be iteratively 
developed during the study to account for insights not 
anticipated.
Analysis
Focus groups will be audio- recorded and transcribed. We 
will use a framework approach to analysis,48 including 
a two- stage process to (1) inductively code transcripts 
followed by (2) a deductive exercise to map identified 
codes to the domains of relevant theoretical frameworks, 
including the TDF, TFA, NPT, in accordance with previous 
research.49 50 Theoretical frameworks will provide a lens 
to deepen our understanding of current FLS practice, 
intervention acceptability and barriers to, and facilita-
tors of intervention implementation. For example, TDF 
domains will be mapped to the COM- B model to iden-
tify intervention functions and theory- driven behaviour 
change techniques.40 Analysis will be undertaken by 
two members of the study team independently, with a 
mapping exercise to explore coding consistency. Find-
ings will be discussed with the wider study team and PAG 
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An electronic survey (using HealthSurvey, hosted by Keele 
University) will be designed and distributed to nurses 
or allied health professionals working in UK FLSs, with 
a target sample size of 80 across the 4 devolved nations. 
The survey will be distributed by the Royal College of 
Physicians Fracture Liaison database national audit, ROS 
mailing lists and by researchers to individuals in their 
known professional networks.
Data collection
Variation in FLS design and specification influences the 
amount of clinician- patient dialogue about drug recom-
mendations, which has direct implications for implemen-
tation of the iFraP intervention and any subsequent trial. 
For example, the extent of patient contact (eg, face- to- 
face, telephone or by letter) will affect the ability to use 
the CDST within the consultation. The specific content 
for the usual care survey will be informed by the focus 
groups, and will aim to describe and quantify the nature 
and amount of discussion FLSs have with patients about 
osteoporotic drugs. Any planned changes in service spec-
ification will also be explored.
Analysis
Any duplicate entries from the same FLS will be checked 
for consistency. If there are any differences, the respon-
dent will be emailed to clarify. A descriptive analysis will 
be undertaken. Findings will be discussed with the CoP to 
discuss implications for iFraP intervention design.
Results of the descriptive analysis will also be used to 
create a detailed FLS typology, based on the extent of 
face- to- face contact to facilitate sampling for the subse-
quent pilot and feasibility trial.
step 3: design and refine the iFrap intervention using field 
testing
The outputs from studies in step 1 and step 2 will be 
integrated to inform design of the CDST and training 
(objective 2, 3b, 3c). iFraP design decision- making will 
be made and documented by the Study Management 
Group.32 Following design of the prototype iFraP consul-
tation intervention (including CDST and training), we 
will conduct three cycles of in- practice (or field) testing 
to assess how the fracture prevention components work 
together, and the acceptability and feasibility of the proto-
type CDST (objective 3d).
Data integration
Data from the evidence synthesis, Delphi survey and focus 
groups will be integrated to add rigour, provide greater 
credibility to results and generate insights about the inter-
vention in development. Integration will be achieved 
using a convergent design and merging of the quantitative 
and qualitative findings using side- by- side joint displays.51
A framework for the consultation will be drafted, informed 
by the consultation stages identified in the evidence synthesis, 
underpinning theory, frameworks of shared decision- making 
and principles of health literacy. This will include a series of 
stages and tasks for the clinician to progress through during 
the consultation, including gathering information, clini-
cian decision- making, eliciting patient knowledge through 
to summarising and signposting. Findings from the Delphi 
analysis (a list of items to be included—and whether they are 
essential or optional, a list of items excluded, and relevant 
free- text comments) and qualitative analysis will be mapped 
to the relevant stage of the consultation in the drafted 
framework. A separate extraction table will be used for joint 
display of other contextual considerations for the interven-
tion, derived from the free- text in the Delphi and qualitative 
findings, and will be organised into considerations with rele-
vance to (i) the tool development, (ii) the training develop-
ment and/or (iii) subsequent trial design.
The joint display will be interrogated to identify ‘meta- 
inferences’:51 confirmed, discordant and expanded find-
ings. Resultant discordant areas, or areas of uncertainty, 
will be presented to the CoP and PAG for further discus-
sion. Following stakeholder discussion, the list of content 
and considerations for (i) tool development, (ii) training 
development and (iii) the trial will be finalised.
iFraP intervention design
Prototype CDST design
The CDST will contain content to support clinician and 
patient decision- making. The patient- facing component will 
be designed with the principles of conversation aids, rather 
than DAs, to support the discussion between clinician and 
patient.52 Frequent stakeholder (CoP and PPIE) workshops 
throughout iFraP- D will allow members to contribute and 
provide insight into CDST design. Insights will be considered 
alongside integration outputs described above in accordance 
with our informed design approach.32 39 The prototype tool 
will be web- based and built using a programmed decision- 
tree based on a modified Markov model (a way to model 
prognosis for clinical problems with ongoing risk). Its 
development will adhere to international guidance and be 
informed by a published and process map for DST devel-
opment.38 A technical production group will manage the 
CDST design. A scientific advisory group of osteoporosis 
academics will advise on the scientific evidence- base that 
will underpin the CDST. Where possible, event rates from 
existing NICE guidelines and meta- analyses will be used. 
PPIE and clinician members of the CoP will informally test 
early CDST prototypes.
Training design
Separately, also informed by stakeholder (CoP and PPIE) 
workshops and integration outputs (eg, list of content and 
considerations for iFraP development), a training develop-
ment group (including input from a behavioural psycholo-
gist, patients, expert nurse educator and expert in shared 
decision- making) will map behaviour change techniques 
targeted to FLS clinician training needs. Qualitative anal-
ysis mapped to the TDF30 aligned with the COM- B model 
will support identification of theory- driven behaviour 
change techniques.29 This process will allow the training 
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development group to develop an evidence- based clinician 
training package and associated training manual.
In-practice testing
Design
We will conduct three cycles of in- practice testing of the 
prototype iFraP consultation in one FLS site. Each of the 
three cycles will consist of five consultations with patients 
and postconsultation interviews. At the end of each cycle, 
the FLS clinician conducting the prototype iFraP consul-
tation will also be interviewed. Each consultation will be 
audio- recorded, observed and contain a ‘think- aloud’ 
interview
Participants
Patients with a recent fragility fracture (n=15) who 
are referred for an FLS consultation and clinicians 
conducting face- to- face FLS consultations (up to n=3). 
In- practice testing will take place at the Haywood Hospital 
FLS chosen for its geographical proximity to the study 
team. The Haywood Hospital FLS operates a one- stop 
model, meaning that if appropriate, patients have a bone 
density scan (dual- energy X- ray absorptiometry), nurse 
assessment, drug treatment recommendation and blood 
tests as part of one consultation.
Data collection and procedures
Patients with FLS appointments will be asked to consent 
to having their consultation observed by a researcher 
and audio- recorded. For each patient participant, the 
researcher will conduct a brief (previously developed) 
warm- up exercise on the ‘think- aloud’ technique prior to 
the consultation.53 In each cycle of consultation and ‘think 
aloud’ interview, a three- step test interview approach will 
be used.54 The topic guide will be developed in collabora-
tion with PAG members.
First, the researcher will observe and listen to the 
test consultation (noting any visual and verbal cues to 
be explored in the interview immediately following the 
consultation) and will make notes using an observation 
schedule. Patients will be asked to mention (aloud, at the 
time they arise) any thoughts and feelings, if they feel 
comfortable to do so, during the consultation as part of a 
‘think- aloud’ process.
Second, patient participants will be interviewed on 
completion of the consultation using predefined and 
spontaneous probes related to iFraP intervention compo-
nents, to follow- up issues that emerged during the consul-
tation (eg, to explore unexpected responses and fill in 
gaps where the participant may not have commented in 
real- time). This step will provide evidence on whether 
risk communication is understood by participants in a 
consistent way and in the way intended, and how well the 
intervention is meeting its objectives.
Third, participants will be invited to explain comments 
made in step 2 and their behaviour during the consulta-
tion, and share views and opinions of the consultation. 
They will be encouraged to say everything they thought 
about each part of the consultation. Participants will be 
invited to contact the researcher if any further thoughts 
come to mind after the interview.
Postconsultation interviews with clinicians will be 
conducted as soon after the last consultation in the cycle 
as possible. A similar three- step approach will be used. In 
the first step however, these clinician participants will be 
played audio clips demonstrating where they explained 
risk, used the CDST and gave recommendations. They 
will be encouraged to think aloud and mention any 
thoughts or feelings during playback. Second and third 
steps will be for patient interviews.
Analysis
The framework approach (as described above for focus 
groups) will be used. The first interviews will be analysed, 
with help from CoP and PAG members to interpret data. 
Relevant changes to iFraP will be made ahead of further 
testing, supported by theoretical frameworks to identify 
and overcome barriers to implementation, enabling an 
iterative cycle moving between user feedback and changes 
to the intervention.
The outcome of this study will finalise a draft iFraP 
intervention and intervention manual to be tested in a 
formal pilot and feasibility trial with nested value of infor-
mation analysis, to evaluate acceptability, feasibility and 
cost- effectiveness.
EthICs And dIssEMInAtIon
Ethics approval for the work outlined in this protocol 
was sought and obtained from North West—Greater 
Manchester West Research Ethics Committee (reference 
number: 19/NW/0559).
Dissemination and knowledge mobilisation will be facil-
itated through national bodies and networks such as the 
ROS, journal papers and conference presentations. The 
results of this study will be made widely and freely avail-
able to all stakeholders; a summary of the results will be 
published on the Keele University and ROS website. PAG 
members will advise on how to translate these into easily 
understandable messages and on how best to disseminate 
the results to the wider public.
In addition to publications in open- access peer- reviewed 
journals, we will use NHS networks and links to profes-
sional bodies to support dissemination of the findings to 
all stakeholders and will use social media to promote the 
findings via our dedicated Twitter and Facebook feeds.
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Supplementary Table 1. Eligibility criteria for osteoporosis guideline evidence synthesis 
Inclusion criteria 
Population  Patients at risk of osteoporosis or with fragility fractures 
Interventions 
 
Clinician-patient consultations to assess risk and initiate/recommend treatment 
for fracture prevention  
Outcomes  Assessment 
Explanations 
Decision-making 
Setting Relevant to UK primary or secondary care  (e.g. UK, European or 
international) 
Date Those guidelines that have been developed, reviewed or revised within 
the past 10 years will be used (2009 to Feb 2019) 
Exclusion criteria 
Guidelines relating to:  
 managing patients already on fracture prevention treatments 
 disease specific conditions (e.g. screening for osteoporosis in inflammatory bowel 
disease) 
 patients with one specific fracture site (e.g. hip fracture) 
 steroid-induced osteoporosis 
 specific countries other than UK 
 fracture assessment and management 
Guidelines related to pre-clinical and animal studies 
Withdrawn guidance   
The original research manuscripts underpinning the guidelines 
Studies not in the English language. 
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